This opportunity funds Stage 2 Protocol Applications for clinical trials of gene-based and gene-targeted therapies targeting ultra-rare neurological diseases. Trials are to be conducted within the NeuroNEXT network, focusing on advancing treatments for these rare conditions.
Eligibility criteria are not specified in the announcement.
